FIELD: chemistry.
SUBSTANCE: invention relates to an improved method of producing calcium salt (E)-7[4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin calcium salt), suitable for making a pharmaceutical drug, useful in treatment of, among others, hypercholesteremia, hyperlipoproteinemia and atherosclerosis. The method involves stages (a)-(g): a) reaction of (1-6C)alkyl ester (E)-(6-{2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[1,3]dioxin-4-yl)acetic acid in an organic solvent mixed with water with aqua acid at high temperature; b) reaction of the obtained solution with aqueous hydroxide of an alkali metal and, possibily, washing the obtained aqueous solution of salt of the alkali metal with a suitable organic solvent; c) bringing the pH of the obtained solution to approximately pH 9-10.5 by adding aqueous hydrochloric acid; d) removal of the organic solvent mixed with water; e) possible filtration of the obtained mixture; f) addition of water soluble calcium salt to the filtrate so that, calcium salt (E)-7[4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(1R,5S)-3,5-dihydroxyhept-6-enoic acid is formed; and g) extraction of product of stage (f). The preferred organic solvent mixed with water is acetonitrile. Aqua acid on stage (a) is hydrochloric acid. Stage (b) involves reaction of the obtained solution with aqueous sodium hydroxide and washing the obtained aqueous solution of sodium salt with a suitable hydrocarbon, ester or ether solvent, for example, toluene, xylol, MTBE (methyl-tert-butyl ether) or ethyl acetate.
EFFECT: improved method.
Title |
Year |
Author |
Number |
METHOD OF ROSUVASTATIN CALCIUM SALT PREPARATION |
2003 |
- Khorberi Dzhon
- Tejlor Najdzhel Filip
|
RU2326871C2 |
METHOD OF PRODUCING ROSUVASTATIN CALCIUM SALT (E) -7-[4-(4-FLUOROPHEHYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATE PRODUCTS THEREOF |
2004 |
- Okada Tetsuo
- Khorberi Dzhon
- Laffan Dejvid Dermot Patrik
|
RU2372349C2 |
CRYSTALLINE FORM OF CALCIUM SALT OF BIS-[(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULPHONYL)AMINO]-PYRIMIDIN-5-YL](3R, 5S)-3, 5-DIHYDROXYHEPT-6-ENOIC ACID |
2004 |
- But Rebekka Dzhejn
- Sittern Piter Ehntoni
- Krabb Dzheffri Norman
- Khorberi Dzhon
- Dzhouns Dejvid Uin Kalvert
|
RU2363697C2 |
7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN -5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID CRYSTALLINE SALTS, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION |
2001 |
- Tehjlor Najdzhel Filip
- Okada Tetsuo
|
RU2265599C2 |
TERTIARY BUTYL-(E)-(6-{2-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL}-(4R,6S)-2,2-DIMETHYL[1,3]DIOXANE-4-YL]ACETATE AND METHOD FOR ITS PREPARING, DIPHENYL-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YLMETHYL]PHOSPHINE OXIDE, METHODS FOR PREPARING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND ITS DERIVATIVES |
2000 |
- Koike Kharuo
- Kabaki Mikio
- Tehjlor Najdzhel Filip
- Dioratsio Lui Dzhozef
|
RU2243969C2 |
PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITOR OF HMG-REDUCTASE |
2000 |
- Krikmor Dzhozef Richard
- Uigginz Norman Al'Fred
|
RU2206324C1 |
CRYSTALLINE HYDRATED FORM OF BIS-[(E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]-PYRIMIDINE-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID] CALCIUM SALT, METHOD FOR ITS PREPARING, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARING AND METHOD FOR TREATMENT |
1999 |
|
RU2236404C2 |
APPLICATION OF ROSUVASTATIN (ZD-4522) IN TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
2001 |
- Rehjza Ali
- Khatchinson Khauard Dzherard
|
RU2294744C2 |
PHARMACEUTICAL COMPOSITION COMPRISING INHIBITOR OF HMG-COA- REDUCTASE |
2000 |
- Krikmor Dzhozef Richard
- Vidzhins Norman Alfred
|
RU2264210C2 |
APPLICATION OF 3-HYDROXY-3-METHTYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS IN PRODUCING MEDICINAL AGENT FOR TREATMENT OF DIABETIC NEUROPATHY |
2000 |
- Kehmeron Norman Judzhin
- Kotter Mehri Ehnn
|
RU2239456C2 |